Back to top
more

Neuronetics (STIM)

(Delayed Data from NSDQ)

$1.85 USD

1.85
206,434

+0.03 (1.65%)

Updated Jul 10, 2024 04:00 PM ET

After-Market: $1.84 -0.01 (-0.54%) 7:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (152 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of 12.12% and 2.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of -266.67% and 19.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

After Plunging 24.2% in 4 Weeks, Here's Why the Trend Might Reverse for Neuronetics (STIM)

by Zacks Equity Research

Neuronetics (STIM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Analysts Estimate Neuronetics (STIM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for August 31st

by Zacks Equity Research

AMWD, CYTK, STIM, OLLI, and THMO have been added to the Zacks Rank #5 (Strong Sell) List on August 31, 2021.

New Strong Sell Stocks for August 25th

by Zacks Equity Research

BEEM, CHRS, KMDA, STIM and PHUN have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2021

New Strong Sell Stocks for August 6th

by Zacks Equity Research

AVA, IDN, KOPN, PRIM, and STIM have been added to the Zacks Rank #5 (Strong Sell) List on August 6, 2021.

Neuronetics (STIM) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of -20.83% and -3.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neuronetics (STIM) Soars 39.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Neuronetics (STIM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of 6.06% and 6.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of 24.00% and 2.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) Soars 6.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Neuronetics (STIM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Neuronetics (STIM) in Focus: Stock Moves 6.8% Higher

by Zacks Equity Research

Neuronetics (STIM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Neuronetics (STIM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of 41.94% and 11.44%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of 19.61% and 16.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Neuronetics (STIM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neuronetics (STIM) Looks Good: Stock Adds 11.3% in Session

by Zacks Equity Research

Neuronetics (STIM) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.

Neuronetics (STIM) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of -54.55% and -3.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

Snap Up These 5 Stocks With Rising P/E

by Sanghamitra Saha

Bet on these top--ranked stocks with rising P/E to realize outsized gains.

    Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Neuronetics (STIM) delivered earnings and revenue surprises of 8.89% and 2.09%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

    Earnings Preview: Neuronetics (STIM) Q4 Earnings Expected to Decline

    by Zacks Equity Research

    Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Neuronetics (STIM) Reports Q3 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Neuronetics (STIM) delivered earnings and revenue surprises of 9.76% and -0.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Neuronetics (STIM) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.